Nitrogen In R Patents (Class 514/626)
-
Publication number: 20090048579Abstract: A pharmaceutical dispenser including a tube having an open end and a space filled with a composition, and an applicator including a first end removably coupled to the open end of the tube and a longitudinal portion with at least one aperture is described. The dispenser can also include a removable cover extending longitudinally and having a bore surrounding the longitudinal portion of the applicator. The composition may be an anal medication. A single dosage unit of the composition is usually contained in the tube, and the tube, applicator, and cover are disposable after use. Methods of using the dispenser include squeezing the tube, allowing the composition to exit the aperture of the applicator, and applying the composition to a target area.Type: ApplicationFiled: August 7, 2008Publication date: February 19, 2009Applicant: NYCOMED US INC.Inventors: Bradley P. Glassman, Alan S. Goldstein, Daniel Glassman
-
Publication number: 20090048347Abstract: The invention relates to a drug delivery system for the topical administration of anesthetic agents. For example, a topical anesthetic for rapid local anesthesia is provided. The topical anesthetic includes an anesthetic, volatile and non-volatile solvents, and an optional thickener. In addition, a method is taught for applying the topical anesthetic to the face of a patient without occlusion. The anesthetic is applied topically to an area for injection such that the dermatological procedure (cosmetic injections) can be performed in fifteen minutes.Type: ApplicationFiled: July 16, 2008Publication date: February 19, 2009Applicant: DermWorx IncorporatedInventors: David M. Cohen, Eugene R. Cooper
-
Publication number: 20090048296Abstract: A transdermal topical anesthetic formulation, which can be used to ameliorate or inhibit neuropathic pain, has been developed. In the preferred embodiment, the topical anesthetic is a local anesthetic such as lidocaine, most preferably lidocaine free-base in a gel, and the dosage of the local anesthetic is effective in the painful area or immediately adjacent areas, to ameliorate or eliminate the pain. High concentration of local anesthetic in solution in the carrier is used to drive rapid release and uptake of the drug. Relief is typically obtained for a period of several hours.Type: ApplicationFiled: August 15, 2008Publication date: February 19, 2009Inventors: James N. Campbell, Arthur F. Michaelis
-
Publication number: 20090042958Abstract: Liquid or semi-liquid pharmaceutical compositions for topically treating immune-mediated skin disorders such as psoriasis, eczema, acne, dermatitis, and skin cancer and methods of treating patients having such immune-mediated skin disorders using the compositions.Type: ApplicationFiled: September 4, 2007Publication date: February 12, 2009Applicant: Geneblue CorporationInventor: Jiajiu Shaw
-
Publication number: 20090036491Abstract: A pharmaceutically delivery system and method of use therefor are described comprising a pharmaceutically active agent and acidified nitrite as an agent to produce local production of nitric oxide at the skin surface. The dosage form may be in any pharmaceutically acceptable carrier means and comprises an acidifying agent adapted to reduce the pH at the environment. In one embodiment, a barrier consisting of a membrane allows diffusions of the anaesthetic and nitrite ions while preventing direct contact of the skin and acidifying agent.Type: ApplicationFiled: September 3, 2008Publication date: February 5, 2009Inventors: Arthur T. Tucker, Nigel Benjamin
-
Publication number: 20090036539Abstract: The present invention concerns new preservative-free hyperbaric compositions of prilocaine HCI intended for use in intrathecal narcosis, characterized by high stability at ambient temperature (15° C.-27° C.). The present invention also concerns a method for manufacturing said compositions.Type: ApplicationFiled: February 14, 2007Publication date: February 5, 2009Applicant: Sintetica S.A.Inventors: Augusto Mitidieri, Elisabetta Donati
-
Publication number: 20090023667Abstract: An object of the present invention is to provide a composition for preventing harmful organisms exerting an excellent control effect against plant diseases and/or insecticidal effect.Type: ApplicationFiled: March 30, 2006Publication date: January 22, 2009Applicant: Mitsui Chemicals, Inc.Inventors: Naofumi Tomura, Kouichi Ebihara, Kunihiko Morizane, Ryutaro Ezaki, Nobuyuki Kawahara, Michikazu Nomura
-
Publication number: 20090012153Abstract: The invention relates to novel compounds of formula (I): H2N—CH(R1)—CH2—S—S—CH2—CH(R2)—CONH—R5, wherein R1 is a hydrocarbon chain, phenyl or benzyl radical, methylene radical substituted by a 5 or 6 atom heterocycle; R2 is a phenyl or benzyl radical, a 5 or 6 atom aromatic heterocycle, methylene group substituted by a 5 or 6 atom heterocycle; R5 is a CH(R3)—COOR4 radical, wherein R3 is hydrogen, an OH or OR group, a saturated hydrocarbon group, a phenyl or benzyl radical and OR4 is hydrophile ester, or 5 or 6 membered heterocycle comprising several heteroatoms selected from a group consisting of nitrogen, sulphur and oxygen, with at least two nitrogene atoms, wherein said heterocycle is substitutable by an alkyl C1-C6, phenyl or benzyl radical.Type: ApplicationFiled: June 26, 2008Publication date: January 8, 2009Applicant: PharmaleadsInventors: Bernard Roques, Marie-Claude Fournie-Zaluski
-
Publication number: 20090004279Abstract: A method for improvement of tolerance for therapeutically effective agents delivered by inhalation comprising a pretreatment of a patient with a nebulized lidocaine or a lidocaine-like compound administered immediately or up to about thirty minutes before administration of the primary therapeutically effective agent. The pretreatment of the patient with the nebulized lidocaine or a lidocaine-like compound improves airway tolerance and deposition of the agent in the lungs and makes such deposition more safe, efficacious, controllable and predictable. The method of the invention is especially useful for enhancement of deposition of immunosuppressive agents in the lung(s) of transplant patients, improved tolerance of the drugs by reducing cough, and improving pulmonary drug deposition.Type: ApplicationFiled: September 10, 2008Publication date: January 1, 2009Inventors: Thomas Hofmann, Alan Bruce Montgomery, Kevin Stapleton, William R. Baker
-
Publication number: 20080312331Abstract: A method is described for the treatment of hypotension, e.g., intra-dialytic hypotension, which is based on the administration to a patient, e.g. a dialysis patient during dialysis, of midodrine or a midodrine metabolite which will increase a lowered blood pressure in the patient or relieve a symptom caused by the dialysis procedure.Type: ApplicationFiled: February 3, 2006Publication date: December 18, 2008Applicant: SOLAPHARM, INC.Inventor: Lawrence Solomon
-
Publication number: 20080306027Abstract: Combretastatin derivatives of formula (I), preparation and use thereof are disclosed, wherein: Rf is alkyl with 1-8 carbon atoms and 1-17 fluorine atoms, R is amino, substituted amino, hydroxyl, nitro, halo, alkyloxy, phosphate or amino acid side chain. Said derivatives have a capability to inhibit the polymerization of microtubules and are useful in treatment against tumor and neovascularization.Type: ApplicationFiled: November 22, 2006Publication date: December 11, 2008Applicant: Zhejiang Dade Pharmaceutical Group Co., Ltd.Inventors: Weiping Shen, Jianping Wang, Jianguo Wang, Feng Qian, Fei Wang, Hongmei Jin
-
Patent number: 7459428Abstract: One aspect of the present invention relates to a method for treating Type II diabetes in an animal, comprising conjointly administering to the animal metformin and an inhibitor of dipeptidylpeptidase IV or a pharmaceutically acceptable salt thereof in an amount sufficient to treat Type II diabetes of the animal.Type: GrantFiled: July 17, 2006Date of Patent: December 2, 2008Assignees: Trustees of Tufts College, New England Medical Center Hospitals, Inc., 1149336 Ontario, Inc.Inventors: William W. Bachovchin, Andrew G. Plaut, Daniel Drucker
-
Publication number: 20080286349Abstract: Systems, devices, and methods for transdermal delivery of one or more therapeutic active agents to a biological interface. A transdermal drug delivery system is provided for passive transdermal delivery of one or more ionizable active agents to a biological interface of a subject. A transdermal drug delivery system includes a backing substrate, and an active agent layer. The active layer includes a thickening agent, a plasticizer, and a therapeutically effective amount of an ionizable active agent.Type: ApplicationFiled: May 16, 2008Publication date: November 20, 2008Inventors: Youhei Nomoto, Kiyoshi Kanamura, Izumi Ishikawa, Mayuko Ishida, Chizuko Ishikawa, Akiyoshi Saito
-
Publication number: 20080249182Abstract: The present invention relates to a novel crystalline modification of N-ethyl-2,2-dichloro-1-methylcyclopropane-carboxamide-2-(2,6-dichloro-?,?,?-trifluoro-p-tolyl)hydrazone, to a process for its preparation and to its use for combating pests and parasites. Further, the invention relates to pesticidal and parasiticidal mixtures and compositions comprising said crystalline modification.Type: ApplicationFiled: October 26, 2006Publication date: October 9, 2008Applicant: BASF SEInventor: Thomas Zierke
-
Publication number: 20080249181Abstract: Antimycorbacterial compositions are disclosed comprising at least one hydroxamate or at least one hydroxamate and at least one hydroxylamine. The preferred ratio of hydroxamate to hydroxylamines is about 100:1 to about 1:1. A method for inhibiting mycobacterial growth is also disclosed comprising the step of administering the compositions of this invention to an animal including a human.Type: ApplicationFiled: August 30, 2004Publication date: October 9, 2008Inventors: Harold Kohn, Myoung Goo Kim, Kurt L. Krause, James M. Briggs, Michael Benedik, Ulrich Strych
-
Patent number: 7432302Abstract: Proliferative cutaneous disease states or conditions are treated by administering a polyamine transport inhibitor R-X-L-polyamine wherein R is a straight or branched C10-50 saturated or unsaturated aliphatic, carboxyalkyl, carbalkoxyalkyl, or alkoxy; a C1-8 alicyclic; a single or multiring aryl substituted or unsubstituted aliphatic; and aliphatic-substituted or unsubstituted single or multiring aromatic; a single or multiring heterocyclic; a single or multiring heterocyclic aliphatic; an aryl sulfonyl; X is —CO—, —SO2—, or —CH2—; and L is a covalent bond or a naturally occurring amino acid, lysine, ornithine, 2,4-diaminobutyric acid, or pharmaceutically acceptable salts thereof or prodrug thereof, and a polyamine biosynthesis inhibitor.Type: GrantFiled: February 23, 2005Date of Patent: October 7, 2008Assignee: MediQuest Therapeutics, Inc.Inventors: Mark R. Burns, Gerard F. Graminski, Nand Baindur, Reitha S. Weeks
-
Publication number: 20080241212Abstract: A biodegradable, flexible covering for a breast implant is provided which comprises one or more biodegradable polymer layers dimensioned and shaped to cover at least a portion of the breast implant. The implant can be inserted into an opening of the covering immediately prior to surgery, but alternate configurations and times of insertion are contemplated as well as open or sheet type devices. The coverings can optionally contain one or more drugs for delivery at the surgical site, particularly for treating or preventing infection, pain, inflammation, capsular contracture, scarring or other complications associated with breast augmentation or breast reconstruction.Type: ApplicationFiled: March 28, 2008Publication date: October 2, 2008Applicant: TYRX PHARMA, INC.Inventors: Arikha Moses, Satish Pulapura, Qing Ge, Sarita Nethula, Irene Shatova, Archana Rajaram
-
Publication number: 20080241245Abstract: The invention relates to a drug delivery device for providing local analgesia, local anesthesia or nerve blockade at a site in a human or animal in need thereof, the device comprising a fibrillar collagen matrix; and at least one drug substance selected from the group consisting of amino amide anesthetics, amino ester anesthetics and mixtures thereof, the at least one drug substance being substantially homogeneously dispersed in the collagen matrix, and the at least one drug substance being present in an amount sufficient to provide a duration of local analgesia, local anesthesia or nerve blockade which lasts for at least about one day after administration.Type: ApplicationFiled: March 28, 2008Publication date: October 2, 2008Inventors: Michael Myers, Philip Wallace Reginald
-
Publication number: 20080241243Abstract: The invention relates to a drug delivery device for providing local analgesia, local anesthesia or nerve blockade at a site in a human or animal in need thereof, the device comprising a fibrillar collagen matrix; and at least one drug substance selected from the group consisting of amino amide anesthetics, amino ester anesthetics and mixtures thereof, the at least one drug substance being substantially homogeneously dispersed in the collagen matrix, and the at least one drug substance being present in an amount sufficient to provide a duration of local analgesia, local anesthesia or nerve blockade which lasts for at least about one day after administration.Type: ApplicationFiled: March 28, 2007Publication date: October 2, 2008Inventors: Michael Myers, Philip Wallace Reginald
-
Publication number: 20080242731Abstract: The present invention relates to topical anaesthetic compositions, uses thereof and methods for their preparation.Type: ApplicationFiled: March 25, 2008Publication date: October 2, 2008Inventors: Thierry Vancaillie, Alan Hewitt
-
Transdermal drug delivery with controlled heat for treating musculoskeletal pain and/or inflammation
Publication number: 20080228151Abstract: Systems and methods for transdermal drug delivery with controlled heat are provided. Such systems can comprise a heating apparatus that includes an exothermic chemical composition, typically in the form of individual heating elements. The heating apparatus can be exposed to ambient oxygen through a cover. The cover can reduce the amount of ambient oxygen capable of contacting the chemical composition compared to when the cover is not present. In some embodiments, the heating apparatus can include more than one heating element. The systems can further include a drug-containing layer that includes a drug. The drug-containing layer can have a surface area of about 50 cm2 to about 400 cm2. The systems of the present invention can be deliver ketoprofen in an amount sufficient to produce a mean blood plasma concentration of ketoprofen in a human subject of at least 45 ng/ml within four hours after initial application of the system to a skin surface.Type: ApplicationFiled: February 28, 2008Publication date: September 18, 2008Inventors: Jie Zhang, Kevin S. Warner, Randal Nelson, Alan Vawdrey, Nathan Strong, Suyi Niu, Michael D. Wessman, Matthew Iverson -
Patent number: 7419972Abstract: The invention relates to new 2-substituted estra-1,3,5(10)-trien-17-ones of formula I as well as their pharmaceutically acceptable salts, their methods of manufacture and use as medicaments for prophylaxis and/or therapy of estrogen-dependent diseases that can be influenced by the inhibition of 17?-hydroxy steroid dehydrogenase type 1.Type: GrantFiled: June 17, 2005Date of Patent: September 2, 2008Assignee: Schering AGInventors: Alexander Hillisch, Olaf Peters, Christian Gege, Wilko Regenhardt, Andrea Rosinus, Jerzy Adamski, Gabriele Moeller, Walter Elger, Birgitt Schneider, Ulrich Bothe
-
Publication number: 20080207762Abstract: A method of treating inflammatory acne vulgaris comprises the topical application of a formulation incorporating carbamide peroxide in a pharmaceutically acceptable vehicle. Inflammatory acneform lesions that can be successfully treated with the inventive method include erythematous papules, pustules, nodules, and cysts. Suitable pharmaceutical vehicles for the topical application of carbamide peroxide include creams, gels, lotions, solutions, suspensions, and ointments.Type: ApplicationFiled: February 25, 2008Publication date: August 28, 2008Applicant: EXOPHARMA, INC.Inventor: Joel E. Bernstein
-
Publication number: 20080207713Abstract: The present invention is directed to compounds, combinations, compositions and methods for enhancing nitric oxide (NO) delivery to target sites, and in particular to muscle, both normal and dystrophic. Enhanced NO delivery according to the present invention may be achieved by using a combination of a muscle relaxant and an NO donor compound, or by using a compound of the invention: formula (I) wherein R1 is H, halo, C1-6 alkoxy or C1-6 alkyl; R2 is H, NO2 or C(O)NH2; R3 is H, NO2 or C(O)NH2; and at least one of R2 and R3 is NO2; or a pharmaceutically acceptable salt of the compound.Type: ApplicationFiled: June 8, 2006Publication date: August 28, 2008Inventors: Gu-Qi Wang, Frank J Burczynski, Judith E Anderson
-
Patent number: 7414039Abstract: The present invention relates to a disorder of the lower urinary tract, and in particular, reducing the symptoms (including treatment) of interstitial cystitis in vivo. In a preferred embodiment, the present invention relates to treatment formulations and methods for reducing interstitial cystitis in patients.Type: GrantFiled: January 27, 2005Date of Patent: August 19, 2008Assignee: The Regents of the University of CaliforniaInventor: C. Lowell Parsons
-
Publication number: 20080193492Abstract: This invention relates to novel compositions and methods of use by which the compositions of this invention are applied topically to one or more body parts of at least two individuals who bring said body parts into contact with the other individual and, when said body parts come into contact with each other, permit the formulations to interact and thereby achieve an unexpected sensation to each individual.Type: ApplicationFiled: August 21, 2007Publication date: August 14, 2008Inventors: Nawaz Ahmad, Cheng-Ji Cui, Bryant Ison
-
Publication number: 20080194649Abstract: The invention concerns a pharmaceutical composition characterised in that it contains a combination of a parasympatholytic agent, a sympathomimetic agent and a local anaesthetic. Such a composition may be injected into the anterior chamber of the eye before a cataract operation or instilled on the eye before laser treatment.Type: ApplicationFiled: March 9, 2006Publication date: August 14, 2008Applicant: LABORATOIRES THEAInventor: Walild Khatib
-
Publication number: 20080182841Abstract: The invention relates to a pharmaceutical composition for relieving pelvic pain or infertility associated with uterine dysrhythmia. The composition includes a locally-administered anti-dysrhythmic treating agent and a bioadhesive extended-release carrier. The composition may be delivered in an extended release formulation that includes a bioadhesive, water-swellable, water-insoluble, cross-linked polycarboxylic acid polymer, such as polycarbophil. The treating agent may be a local anesthetic, such as lidocaine. The invention also relates to a method of treating or preventing pelvic pain, or treating or improving infertility, by inserting a mixture of an anti-dysrhythmic treating agent and a bioadhesive carrier into the vagina of the patient to be treated.Type: ApplicationFiled: September 4, 2007Publication date: July 31, 2008Inventors: Howard L. Levine, William J. Bologna, Dominique De Zeigler
-
Publication number: 20080176948Abstract: A topical anesthetic for rapid local anesthesia is provided. The topical anesthetic includes an anesthetic, volatile and non-volatile solvents, and a thickener. In addition, a method is taught for applying the topical anesthetic to the face of a patient without occlusion. The anesthetic is applied topically to an area for injection such that the dermatological procedure (cosmetic injections) can be performed in fifteen minutes.Type: ApplicationFiled: January 16, 2008Publication date: July 24, 2008Applicant: DERMWORX, INC.Inventors: David M. Cohen, Eugene R. Cooper
-
Patent number: 7402601Abstract: The use of compound 1 and/or 2 of the formulae and of physiologically tolerable salts of compound 2 for the treatment of rejection reactions of the organ recipient to the transplanted organ is described.Type: GrantFiled: July 25, 2003Date of Patent: July 22, 2008Assignee: Sanofi-Aventis Deutschland GmbHInventor: Robert Ryder Bartlett
-
Publication number: 20080166413Abstract: In certain embodiments, the present invention is directed to a pharmaceutical formulation for topical administration on a mammal, comprising a unit dose of a therapeutically effective amount of a therapeutic agent and a pharmaceutically acceptable carrier medium therefor, said formulation being solid at ambient temperature and having a softening point of not higher than 35° C., such that when the formulation is placed in continuous contact with the skin of a mammalian patient, it is softened to a consistency to effect substantial application of the unit dose of said therapeutic agent onto a desired skin area of the mammalian patient within a time period of less than 10 minutes.Type: ApplicationFiled: March 19, 2008Publication date: July 10, 2008Applicant: PharmaKodex LimitedInventors: John Nicholas Staniforth, Michael John Tobyn
-
Publication number: 20080146642Abstract: The invention relates to methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid (3APS) in a subject, preferably a human subject. The invention encompasses compounds that will yield or generate 3APS, either in vitro or in vivo. Preferred compounds include amino acid prodrugs of 3APS for use, including but not limited to, the prevention and treatment of Alzheimer's disease.Type: ApplicationFiled: October 12, 2007Publication date: June 19, 2008Inventors: Xianqi Kong, Mohamed Atfani, Benoit Bachand, Abderrahim Bouzide, Stephane Ciblat, Sophie Levesque, David Migneault, Isabelle Valade, Xinfu Wu, Daniel Delorme
-
Publication number: 20080145434Abstract: Methods of attenuating the toxic or medically undesirable effects of drugs and toxins in a human by administering to a human an injectable formulation comprised of a dispersion of particles comprised of reversed cubic or reversed hexagonal lyotropic liquid crystalline material. The particles absorb or adsorb or otherwise sequester and attenuate the effect of drugs and toxins, and may be used as a rescue or reversal agent, or as a prophylaxis. The invention is especially applicable in reversing adverse effects of local anesthetics inadvertently delivered systemically, and attenuating the therapeutic effects of general anesthetics in the course of treatment.Type: ApplicationFiled: December 6, 2007Publication date: June 19, 2008Inventors: David M. Anderson, Vincent M. Conklin, Benjamin G. Cameransi
-
Publication number: 20080146672Abstract: A pharmaceutical anesthetic composition for topical administration for dental, emergency and general medical use is described. The composition is a eutectic composition of anesthetic agents, sugar alcohol, and menthol for the purpose of numbing oral or dermal tissue. Methods of making and of using the composition are described.Type: ApplicationFiled: December 7, 2007Publication date: June 19, 2008Inventors: Marcia Marye DENTON, Jerry A. Rogers
-
Publication number: 20080146527Abstract: Novel florfenicol compounds having the chemical structure: or a pharmaceutically-acceptable salt thereof or a solvate thereof, or prodrug thereof, wherein R1 is CHCl2, CHClF, CHF2, CHBrCl, CH3, CH2N3, CH2CN, CH(R2)NH2 or CH X1X2; where R2 is H, CH3 or CH2OH, and X1 and X2 are independently selected halogens; and R3 is CH2Cl, CH2F, CHF2, CHCl2 or CH2OH are disclosed. The compounds are useful for the treatment and/or prevention of bacterial infections in a broad range of patients such as, without limitation, birds, fish, shellfish and mammals.Type: ApplicationFiled: February 27, 2008Publication date: June 19, 2008Inventors: Dale E. Shuster, Scott Hecker, Tomasz W. Glinka, Rajeshwar Singh, Zhuoyi Su
-
Publication number: 20080108700Abstract: It is an object of the present invention to provide an external preparation having enhanced transdermal penetration of a mast cell degranulation inhibitor. It is also an object of the present invention to provide a method for improving the photostability of a preparation containing a mast cell degranulation inhibitor. The present invention provides an external preparation containing a mast cell degranulation inhibitor and a topical anesthetic. Further, the method for enhancing the photostability of a preparation containing a mast cell degranulation inhibitor according to the present invention includes adding a topical anesthetic thereto.Type: ApplicationFiled: August 1, 2005Publication date: May 8, 2008Inventors: Mitsuru Endo, Keiko Yamasaki, Hidetoshi Hamamoto, Sueko Matsumura, Masaki Ishibashi
-
Patent number: 7354954Abstract: According to the subject invention, there is disclosed a method for treating a patient/subject having a spastic disorder, a convulsive disorder, pain or epilepsy which includes administering to the subject having any one of these conditions a therapeutically effective amount of the compound gamma-aminobutyramide, analogs, substituted forms, derivatives, the pharmaceutically acceptable salts, esters, amides, and prodrugs thereof, or compounds which yield gamma-aminobutyramide as an intermediate, a metabolite, or a by-product.Type: GrantFiled: August 10, 2000Date of Patent: April 8, 2008Inventors: Jay M. Meythaler, Jean Peduzzi
-
Patent number: 7345096Abstract: The present invention relates to the use of compounds and composition of compounds that modulate norepinephrine levels for the prevention and treatment of vasomotor symptoms, such as hot flush, caused by, inter alia, thermoregulatory dysfunctions.Type: GrantFiled: October 14, 2003Date of Patent: March 18, 2008Assignee: WyethInventors: Darlene Coleman Deecher, Istvan Jozsef Merchenthaler, Liza Leventhal, Kimberly Jean Sipe, Lawrence Thomas O'Connor
-
Publication number: 20080039431Abstract: A method of improving the growth of a plant is provided by reducing the incidence of one or more insect-vectored viral infections. The method comprises the step of applying a primary treatment composition in-furrow during planting of a seed or seedling or during transplanting of the plant, wherein the primary treatment composition comprises an effective amount of a fungicide such as prothioconazole.Type: ApplicationFiled: August 1, 2007Publication date: February 14, 2008Inventors: Charles L. Cleary, Richard D. Rudolph, John E. Curtis, George H. Musson
-
Publication number: 20080026014Abstract: A stick for the topical or transmucosal application of a skin care or active agent onto and via the nasal mucosa, respectively, is provided, wherein the stick material contains a composition of at least one carrier substance and at least one skin care or active agent, which is capable of acting on the nasal mucosa and/or being resorbed by it or which contains at least one volatile substance that acts on the deeper respiratory tract and/or is being resorbed by the deeper respiratory tract. Furthermore, the use of a medical skin care or cosmetical stick or of a stick material or of a refill cartridge containing said material for the topical or transmucosal application is described.Type: ApplicationFiled: October 31, 2003Publication date: January 31, 2008Inventor: Olaf Michel
-
Publication number: 20080021068Abstract: Disclosed is a stable aqueous gel formulation suitable for topical use comprising water, an anesthetic (e.g., lidocaine hydrochloride), a viscoelastic polymer, and a tonicity modifier, wherein the aqueous gel formulation is free of preservatives and phosphate buffer, is isotonic with physiological fluids, and is sterile and has low particulate count. Also disclosed is a method of inducing topical anesthesia on a tissue or organ, e.g., the eye, of an animal comprising providing a stable aqueous gel formulation comprising water, an anesthetic, a viscoelastic polymer, and a tonicity modifier, wherein the aqueous gel formulation is free of preservatives and phosphate buffer, is isotonic with physiological fluids, and is sterile, and topically administering an effective amount of the aqueous gel formulation to the tissue or organ of the animal.Type: ApplicationFiled: July 24, 2006Publication date: January 24, 2008Applicant: Akorn, Inc.Inventors: Abu Alam, Elias Reichel, Brandon Busbee
-
Patent number: 7316815Abstract: The invention concerns the use in a cosmetic composition of at least a poly-aminoacid of general formula (I) in which X is —O—, —S— or —NR3; R1 represents in particular a hydrogen atom or a C1-C40 alkyl radical; R2 represents in particular a hydrogen atom or an optionally substituted alkyl radical; R3 represents a hydrogen atom or an alkyl radical; R4 represents a hydrogen atom or a radical such as NH2, OH, SH, —CHOHCH3, —CONH2; n is a number greater than 1 such that the poly-aminoacid derivative molecular weight ranges between 200 and 200000.Type: GrantFiled: October 10, 2003Date of Patent: January 8, 2008Assignee: L'Oreal S.A.Inventors: Michel Philippe, Christian Blaise
-
Patent number: 7273887Abstract: The topical anesthetic formulation of the present invention is typically a solution that preferably includes lidocaine, USP as the active anesthetic ingredient with benzyl alcohol and isopropyl alcohol. This invention deals with problems commonly associated with topical application of local anesthetics such as: slow onset of action; need for occlusion; messiness of creams, ointments or gels; and rapid loss of effect due to rapid systemic dispersion. The invention permits enhanced penetration of the anesthetic and thereby allows for a lesser total dosage of pharmaceutically active ingredient. The use of a lesser total dosage also decreases systemic toxicity.Type: GrantFiled: October 23, 2000Date of Patent: September 25, 2007Assignee: Transdermatech, Inc.Inventor: Scott Wepfer
-
Patent number: 7241812Abstract: The present invention relates to compounds which modulate the activity of the S1P1 receptor, the use of these compounds for treating conditions associated with signaling through the S1P1 receptor, and pharmaceutical compositions comprising these compounds.Type: GrantFiled: August 12, 2005Date of Patent: July 10, 2007Assignee: Praecis Pharmaceuticals, Inc.Inventors: Ashis K. Saha, Malcolm J. Kavarana, Ghotas Evindar, Alexander L. Satz, Barry Morgan
-
Patent number: 7208528Abstract: Novel inhibitors of polyamine transport having inhibition constants two orders of magnitude lower than those of known compounds are disclosed. These polyamine analogues are useful pharmaceutical agents for treating diseases where it is desired to inhibit polyamine transport or other polyamine binding proteins, for example cancer and post-angioplasty injury. Novel chemical synthetic methods to obtain polyamine analogues are disclosed, including the production of a combinational polyamine library. These approaches yield analogues with desirable activities both for diagnostic and research assays and therapy. The assays of the invention are useful for high throughput screening of targets in the discovery of drugs that interact with the polyamine system.Type: GrantFiled: September 15, 1999Date of Patent: April 24, 2007Assignee: MediQuest Therapeutics, Inc.Inventors: Nicolaas M. J. Vermeulin, Christine L. O'Day, Heather K. Webb, Mark R. Burns, Donald E. Bergstrom
-
Patent number: 7160923Abstract: Novel inhibitors of polyamine transport having inhibition constants two orders of magnitude lower than those of known compounds are disclosed. These polyamine analogues are useful pharmaceutical agents for treating diseases where it is desired to inhibit polyamine transport or other polyamine binding proteins, for example cancer and post-angioplasty injury. Novel chemical synthetic methods to obtain polyamine analogues are disclosed, including the production of a combinatiorial polyamine library. These approaches yield analogues with desirable activities both for diagnostic and research assays and therapy. The assays of the invention are useful for high throughput screening of targets in the discovery of drugs that interact with the polyamine system.Type: GrantFiled: November 14, 2000Date of Patent: January 9, 2007Assignee: MediQuest Therapeutics, Inc.Inventors: Nicolaas M. J. Vermeulin, Christine L. O'Day, Heather K. Webb, Mark R. Burns, Donald E. Bergstrom
-
Patent number: 7157429Abstract: The present invention provides methods and compositions for modification and regulation of glucose and lipid metabolism, generally to reduce insulin resistance, hyperglycemia, hyperinsulinemia, obesity, hyperlipidemia, hyperlipoproteinemia (such as chylomicrons, VLDL and LDL), and to regulate body fat and more generally lipid stores, and, more generally, for the improvement of metabolism disorders, especially those associated with diabetes, obesity and/or atherosclerosis. The compositions of the present invention include dipeptidylpeptidase inhibitors, which are able to inhibit the proteolysis of GLP-1 and accordingly increase the plasma half-life of that hormone. The subject inhibitors may be peptidyl, peptidomimetic (e.g. boronyl peptidomimetics), or non-peptidyl nitrogen containing heterocycles.Type: GrantFiled: July 28, 2000Date of Patent: January 2, 2007Assignee: Trustees of Tufts CollegeInventors: William A. Bachovchin, Andrew G. Plaut, Daniel Drucker
-
Patent number: 7119229Abstract: Colchicine derivatives represented by the formula (I) with a halogen or nitric ester group, or pharmaceutically acceptable salts thereof, are described. Pharmaceutical compositions containing the same as effective components are also described. The colchicine derivatives were found to have anticancer, anti-proliferous and immunosuppressive function. Methods for preparing the colchicines derivatives are also provided.Type: GrantFiled: May 27, 2002Date of Patent: October 10, 2006Assignees: Chemtech Research Incorporation, KT & G CorporationInventors: Wan Joo Kim, Kyoung Soo Kim, Myung Hwa Kim, Jong Yek Park, Jung Min Jang, Jae Won Choi, Dong Hoo Kim
-
Patent number: 7078381Abstract: The present invention provides methods and compositions for modifying glucose metabolism and treating Type II diabetes in an animal, along with modifying metabolism of a peptide hormone in an animal. Compositions disclosed herein comprise one or more peptides and/or peptide analogs which include a functional group that reacts with an active site residue of a protease.Type: GrantFiled: March 4, 2004Date of Patent: July 18, 2006Assignee: Trustees of Tufts CollegeInventors: William W. Bachovchin, Andrew G. Plaut, Daniel Drucker
-
Patent number: 7071232Abstract: The present invention relates to peptide-like compounds, e.g. aminocarboxylic acid amide derivatives, and to methods of using same in the field of general health care, for example, to improve resistance to stress, improve production of desired characteristics or useful products in animals, to increase weight gain, prevent diseases caused by pathogens, and to decrease feed efficiency. The invention has applications in the field of animal husbandry, and in treating or preventing weight loss associated with a disease in humans. It also relates to administering carbobenzoxy beta-alanyl taurine to improve feed efficiency in an animal, comprising administering to the animal an amount of carbobenzoxy beta-alanyl taurine sufficient to reduce the amount of food required to increase a unit of weight in the animal.Type: GrantFiled: August 14, 2000Date of Patent: July 4, 2006Inventor: Floyd E. Taub